- Home
- PHAT vs IMOS Comparison
PHAT vs IMOS Comparison
Compare PHAT & IMOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- IMOS
- Stock Information
- Founded
- PHAT 2018
- IMOS 1997
- Country
- PHAT United States
- IMOS Taiwan
- Employees
- PHAT N/A
- IMOS N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- IMOS Semiconductors
- Sector
- PHAT Health Care
- IMOS Technology
- Exchange
- PHAT Nasdaq
- IMOS Nasdaq
- Market Cap
- PHAT 727.5M
- IMOS 666.7M
- IPO Year
- PHAT 2019
- IMOS N/A
- Fundamental
- Price
- PHAT $9.80
- IMOS $18.54
- Analyst Decision
- PHAT Strong Buy
- IMOS
- Analyst Count
- PHAT 5
- IMOS 0
- Target Price
- PHAT $16.40
- IMOS N/A
- AVG Volume (30 Days)
- PHAT 4.9M
- IMOS 21.2K
- Earning Date
- PHAT 08-07-2025
- IMOS 08-12-2025
- Dividend Yield
- PHAT N/A
- IMOS 4.58%
- EPS Growth
- PHAT N/A
- IMOS N/A
- EPS
- PHAT N/A
- IMOS 0.05
- Revenue
- PHAT $81,859,000.00
- IMOS $685,506,006.00
- Revenue This Year
- PHAT $195.45
- IMOS N/A
- Revenue Next Year
- PHAT $106.76
- IMOS $2.21
- P/E Ratio
- PHAT N/A
- IMOS $19.22
- Revenue Growth
- PHAT 3055.70
- IMOS 2.89
- 52 Week Low
- PHAT $2.21
- IMOS $12.78
- 52 Week High
- PHAT $19.71
- IMOS $26.91
- Technical
- Relative Strength Index (RSI)
- PHAT 66.25
- IMOS 56.45
- Support Level
- PHAT $8.86
- IMOS $18.57
- Resistance Level
- PHAT $11.21
- IMOS $19.78
- Average True Range (ATR)
- PHAT 1.59
- IMOS 0.62
- MACD
- PHAT -0.06
- IMOS -0.09
- Stochastic Oscillator
- PHAT 63.60
- IMOS 46.04
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.